Cargando…

Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma

OBJECTIVES: Among advanced multiple myeloma (MM) patients, B-cell maturation antigen (BCMA) specific targets like Belantamab Mafodotin (belamaf) and CAR T-cell therapies have been shown to improve clinical outcomes, but at significant costs. To compare the expected costs per quality-adjusted life ye...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapinos, Kandice A., Hu, Ellen, Trivedi, Jigar, Geethakumari, Praveen Ramakrishnan, Kansagra, Ankit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869188/ https://www.ncbi.nlm.nih.gov/pubmed/36651055 http://dx.doi.org/10.1177/10732748221142945

Ejemplares similares

Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies
por: Mahimainathan, Lenin, et al.
Publicado: (2020)

Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
por: Gajra, Ajeet, et al.
Publicado: (2022)

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
por: Geethakumari, Praveen Ramakrishnan, et al.
Publicado: (2021)

P836: ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA
por: Bielowski, Anna, et al.
Publicado: (2023)

Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
por: Mulgaonkar, Aditi, et al.
Publicado: (2023)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
por: Xing, Lijie, et al.
Publicado: (2023)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Brief Cost Analysis of Surgical Personal Protective Equipment During the COVID-19 Pandemic
por: Kapinos, Kandice A., et al.
Publicado: (2022)

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma
por: Jagannath, Sundar, et al.
Publicado: (2023)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma
por: Mohan, Meera, et al.
Publicado: (2021)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022)

Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
por: Yu, Bo, et al.
Publicado: (2019)

Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
por: Hartley-Brown, Monique, et al.
Publicado: (2022)

Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
por: Ray, Upasana, et al.
Publicado: (2023)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
por: Berahovich, Robert, et al.
Publicado: (2018)

Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Cesarean deliveries and maternal weight retention
por: Kapinos, Kandice A., et al.
Publicado: (2017)

CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
por: Rodríguez-Otero, Paula, et al.
Publicado: (2020)

Recent updates on CAR T clinical trials for multiple myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma
por: Jasiński, Marcin, et al.
Publicado: (2021)

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma
por: Sjöstrand, Maria, et al.
Publicado: (2023)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2020)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021)

New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma
por: McClanahan, Alli, et al.
Publicado: (2022)

Road testing new CAR design strategies in multiple myeloma
por: Rana, Priyanka S., et al.
Publicado: (2022)

Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
por: Roex, Gils, et al.
Publicado: (2020)

CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
por: Rendo, Matthew J, et al.
Publicado: (2022)

Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
por: Zhang, Xiaohui, et al.
Publicado: (2023)

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
por: Gahrton, Gösta
Publicado: (2023)

Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma
por: Awuah, Dennis, et al.
Publicado: (2023)

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
por: Zhang, Xiaomin, et al.
Publicado: (2023)

Single VHH-directed BCMA CAR-NK cells for multiple myeloma
por: Ren, Quan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0or0s78c4tej75hi4jdjql9abu